10 July 2025 - Submission of marketing authorization application to the EMA seeking approval for investigational low dose gadoquatrane for contrast-enhanced magnetic resonance imaging of all body regions for adults and paediatric patients including neonates.

Bayer today announced the submission of a marketing authorisation application to the European Medicines Agency for its investigational contrast agent gadoquatrane for contrast enhancement in magnetic resonance imaging to detect and visualise known or suspected pathologies in all body regions and the central nervous system in adults and paediatric patients including neonates.

Read Bayer press release